ArticleKidney international reports2021

Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design.

Liron Walsh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.